Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27493
IPSCIO Record ID: 26530
IPSCIO Record ID: 5426
Licensor grants, subject to the terms of this Agreement, to GBI a worldwide, perpetual and non-exclusive sublicense to make, use and create Improvements to Proteins and Antibodies solely in the research, development and sale of additional antibodies and/or diagnostic assays solely for the diagnosis of breast, prostate and/or ovarian cancers. Also includes to make, have made, use and create Improvements to the Mammastatin Serum Assay and the Know-How solely in the research, development and sale of Additional Products.
Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How
P&O TECHNOLOGY shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that BIOTHERAPIES cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.
IPSCIO Record ID: 4246
Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How .
IPSCIO Record ID: 4006
August 28, 2016
August 28, 2016
November 14, 2020
November 14, 2020
August 28, 2016
Patent Application 20060030787
IPSCIO Record ID: 372515
The New MUC1 Invention means any invention related and pertaining to
— MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof; and
— methods of making and using any MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof for the detection, evaluation, prevention and/or treatment of cancer.
Peptide means any peptide, polypeptide or protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof which is covered by a Valid Claim of the Licensed Patents.
IPSCIO Record ID: 383584
Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.
ErbituxÂ® shall mean cetuximab, and marketed as ErbituxÂ®.
ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.
The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.
IPSCIO Record ID: 27645
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5
4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas
5,286,647 – human-human hybridomas for neoplasms
5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.
5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.
6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions
6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
6,051,693 – CLNH11-specific antibodies
6,090,924 – human-human CLNH5-specific antibodies
6,165,467 – stabilized human monoclonal antibody preparation
The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company